Global Glial Cell Line Derived Neurotrophic Factor Market

Glial Cell Line Derived Neurotrophic Factor Comprehensive Study by Type (GSK-812, LAUR-301, TW-002, AMT-090, Other), Application (Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson’s Disease, Retinal Degeneration, Others) Players and Region - Global Market Outlook to 2030

Glial Cell Line Derived Neurotrophic Factor Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Glial Cell Line Derived Neurotrophic Factor
The glial cell-derived neurotrophic factor is defined as the small protein which potently promotes the survival of numerous types of neurons. In addition, it is mostly found to be effective in preventing the apoptosis of motor neurons which is induced by axotomy. Brain ischemia, retinal degeneration, Parkinson's disease, amyotrophic lateral sclerosis are some of the major application of glial cell line-derived neurotrophic factor market. According to an article published by the Parkinson Association of the Carolinas, more than 7 to 10 million people are suffering from Parkinson's disease. Hence, growth in the aging population and the associated increase in the prevalence of Parkinson's disease and government funding for research are likely to be a prime driver for the global Parkinson's disease treatment market

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.6%


Leading global players are focusing on strategic partnerships to improve their products and services. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Analyst at AMA Research estimates that Netherlands Players will contribute the maximum growth to Global Glial Cell Line Derived Neurotrophic Factor market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline Plc (United Kingdom), Treeway BV (Netherlands) and UniQure NV (Netherlands) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Glial Cell Line Derived Neurotrophic Factor market by Type (GSK-812, LAUR-301, TW-002, AMT-090 and Other), Application (Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson’s Disease, Retinal Degeneration and Others) and Region.



On the basis of geography, the market of Glial Cell Line Derived Neurotrophic Factor has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Advancements in Technology have linked the Importance of GDNF in the Treatment of Parkinson’s disease,

Market Growth Drivers:
Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson ’s Disease and Government Funding for Research and Rising Healthcare Awareness Globally

Challenges:
The problem regarding Strong Drug Pipeline

Restraints:
Issue related to Availability of Alternative Treatments

Opportunities:
Rising Demand from Emerging Economics such as China, India, among others and Government Initiatives to Expand the Glial Cell Line-Derived Neurotrophic Factor Market

Market Leaders and their expansionary development strategies
In September 2021, MedGenesis Therapeutix announced a partnership with Parkinson's UK to create Vivifi Biotech, a dedicated company focused on researching GDNF as a potential treatment for Parkinson's disease. This partnership aimed to further develop MedGenesis' existing GDNF program and investigate its potential to regenerate brain cells in Parkinson's patients.
In April 2022, AskBio, a gene therapy company, announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to develop and commercialize gene therapy using AAV2-GDNF for Parkinson's disease. This partnership aimed to leverage AskBio's gene therapy expertise to deliver GDNF directly to brain cells, potentially offering a more targeted and sustained treatment for Parkinson's.


Key Target Audience
Glial Cell-Derived Neurotrophic Factor Manufacturers, Regulatory bodies, Intermediary Suppliers and End Users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • GSK-812
  • LAUR-301
  • TW-002
  • AMT-090
  • Other
By Application
  • Amyotrophic Lateral Sclerosis
  • Brain Ischemia
  • Parkinson’s Disease
  • Retinal Degeneration
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson ’s Disease
      • 3.2.2. Government Funding for Research and Rising Healthcare Awareness Globally
    • 3.3. Market Challenges
      • 3.3.1. The problem regarding Strong Drug Pipeline
    • 3.4. Market Trends
      • 3.4.1. Advancements in Technology have linked the Importance of GDNF in the Treatment of Parkinson’s disease,
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Glial Cell Line Derived Neurotrophic Factor, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Glial Cell Line Derived Neurotrophic Factor (Value)
      • 5.2.1. Global Glial Cell Line Derived Neurotrophic Factor by: Type (Value)
        • 5.2.1.1. GSK-812
        • 5.2.1.2. LAUR-301
        • 5.2.1.3. TW-002
        • 5.2.1.4. AMT-090
        • 5.2.1.5. Other
      • 5.2.2. Global Glial Cell Line Derived Neurotrophic Factor by: Application (Value)
        • 5.2.2.1. Amyotrophic Lateral Sclerosis
        • 5.2.2.2. Brain Ischemia
        • 5.2.2.3. Parkinson’s Disease
        • 5.2.2.4. Retinal Degeneration
        • 5.2.2.5. Others
      • 5.2.3. Global Glial Cell Line Derived Neurotrophic Factor Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Glial Cell Line Derived Neurotrophic Factor: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Treeway BV (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. UniQure NV (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
  • 7. Global Glial Cell Line Derived Neurotrophic Factor Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Glial Cell Line Derived Neurotrophic Factor (Value)
      • 7.2.1. Global Glial Cell Line Derived Neurotrophic Factor by: Type (Value)
        • 7.2.1.1. GSK-812
        • 7.2.1.2. LAUR-301
        • 7.2.1.3. TW-002
        • 7.2.1.4. AMT-090
        • 7.2.1.5. Other
      • 7.2.2. Global Glial Cell Line Derived Neurotrophic Factor by: Application (Value)
        • 7.2.2.1. Amyotrophic Lateral Sclerosis
        • 7.2.2.2. Brain Ischemia
        • 7.2.2.3. Parkinson’s Disease
        • 7.2.2.4. Retinal Degeneration
        • 7.2.2.5. Others
      • 7.2.3. Global Glial Cell Line Derived Neurotrophic Factor Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Glial Cell Line Derived Neurotrophic Factor: by Type(USD Million)
  • Table 2. Glial Cell Line Derived Neurotrophic Factor GSK-812 , by Region USD Million (2018-2023)
  • Table 3. Glial Cell Line Derived Neurotrophic Factor LAUR-301 , by Region USD Million (2018-2023)
  • Table 4. Glial Cell Line Derived Neurotrophic Factor TW-002 , by Region USD Million (2018-2023)
  • Table 5. Glial Cell Line Derived Neurotrophic Factor AMT-090 , by Region USD Million (2018-2023)
  • Table 6. Glial Cell Line Derived Neurotrophic Factor Other , by Region USD Million (2018-2023)
  • Table 7. Glial Cell Line Derived Neurotrophic Factor: by Application(USD Million)
  • Table 8. Glial Cell Line Derived Neurotrophic Factor Amyotrophic Lateral Sclerosis , by Region USD Million (2018-2023)
  • Table 9. Glial Cell Line Derived Neurotrophic Factor Brain Ischemia , by Region USD Million (2018-2023)
  • Table 10. Glial Cell Line Derived Neurotrophic Factor Parkinson’s Disease , by Region USD Million (2018-2023)
  • Table 11. Glial Cell Line Derived Neurotrophic Factor Retinal Degeneration , by Region USD Million (2018-2023)
  • Table 12. Glial Cell Line Derived Neurotrophic Factor Others , by Region USD Million (2018-2023)
  • Table 13. South America Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2018-2023)
  • Table 14. South America Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 15. South America Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 16. Brazil Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 17. Brazil Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 18. Argentina Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 19. Argentina Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 20. Rest of South America Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 21. Rest of South America Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 22. Asia Pacific Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2018-2023)
  • Table 23. Asia Pacific Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 24. Asia Pacific Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 25. China Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 26. China Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 27. Japan Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 28. Japan Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 29. India Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 30. India Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 31. South Korea Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 32. South Korea Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 33. Taiwan Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 34. Taiwan Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 35. Australia Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 36. Australia Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 38. Rest of Asia-Pacific Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 39. Europe Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2018-2023)
  • Table 40. Europe Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 41. Europe Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 42. Germany Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 43. Germany Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 44. France Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 45. France Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 46. Italy Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 47. Italy Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 48. United Kingdom Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 49. United Kingdom Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 50. Netherlands Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 51. Netherlands Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 52. Rest of Europe Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 53. Rest of Europe Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 54. MEA Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2018-2023)
  • Table 55. MEA Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 56. MEA Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 57. Middle East Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 58. Middle East Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 59. Africa Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 60. Africa Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 61. North America Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2018-2023)
  • Table 62. North America Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 63. North America Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 64. United States Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 65. United States Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 66. Canada Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 67. Canada Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 68. Mexico Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2018-2023)
  • Table 69. Mexico Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2018-2023)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Glial Cell Line Derived Neurotrophic Factor: by Type(USD Million)
  • Table 74. Glial Cell Line Derived Neurotrophic Factor GSK-812 , by Region USD Million (2025-2030)
  • Table 75. Glial Cell Line Derived Neurotrophic Factor LAUR-301 , by Region USD Million (2025-2030)
  • Table 76. Glial Cell Line Derived Neurotrophic Factor TW-002 , by Region USD Million (2025-2030)
  • Table 77. Glial Cell Line Derived Neurotrophic Factor AMT-090 , by Region USD Million (2025-2030)
  • Table 78. Glial Cell Line Derived Neurotrophic Factor Other , by Region USD Million (2025-2030)
  • Table 79. Glial Cell Line Derived Neurotrophic Factor: by Application(USD Million)
  • Table 80. Glial Cell Line Derived Neurotrophic Factor Amyotrophic Lateral Sclerosis , by Region USD Million (2025-2030)
  • Table 81. Glial Cell Line Derived Neurotrophic Factor Brain Ischemia , by Region USD Million (2025-2030)
  • Table 82. Glial Cell Line Derived Neurotrophic Factor Parkinson’s Disease , by Region USD Million (2025-2030)
  • Table 83. Glial Cell Line Derived Neurotrophic Factor Retinal Degeneration , by Region USD Million (2025-2030)
  • Table 84. Glial Cell Line Derived Neurotrophic Factor Others , by Region USD Million (2025-2030)
  • Table 85. South America Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2025-2030)
  • Table 86. South America Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 87. South America Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 88. Brazil Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 89. Brazil Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 90. Argentina Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 91. Argentina Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 92. Rest of South America Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 93. Rest of South America Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 94. Asia Pacific Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2025-2030)
  • Table 95. Asia Pacific Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 96. Asia Pacific Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 97. China Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 98. China Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 99. Japan Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 100. Japan Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 101. India Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 102. India Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 103. South Korea Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 104. South Korea Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 105. Taiwan Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 106. Taiwan Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 107. Australia Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 108. Australia Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 110. Rest of Asia-Pacific Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 111. Europe Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2025-2030)
  • Table 112. Europe Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 113. Europe Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 114. Germany Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 115. Germany Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 116. France Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 117. France Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 118. Italy Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 119. Italy Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 120. United Kingdom Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 121. United Kingdom Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 122. Netherlands Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 123. Netherlands Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 124. Rest of Europe Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 125. Rest of Europe Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 126. MEA Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2025-2030)
  • Table 127. MEA Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 128. MEA Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 129. Middle East Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 130. Middle East Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 131. Africa Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 132. Africa Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 133. North America Glial Cell Line Derived Neurotrophic Factor, by Country USD Million (2025-2030)
  • Table 134. North America Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 135. North America Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 136. United States Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 137. United States Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 138. Canada Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 139. Canada Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 140. Mexico Glial Cell Line Derived Neurotrophic Factor, by Type USD Million (2025-2030)
  • Table 141. Mexico Glial Cell Line Derived Neurotrophic Factor, by Application USD Million (2025-2030)
  • Table 142. Research Programs/Design for This Report
  • Table 143. Key Data Information from Secondary Sources
  • Table 144. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Glial Cell Line Derived Neurotrophic Factor: by Type USD Million (2018-2023)
  • Figure 5. Global Glial Cell Line Derived Neurotrophic Factor: by Application USD Million (2018-2023)
  • Figure 6. South America Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 7. Asia Pacific Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 8. Europe Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 9. MEA Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 10. North America Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 11. Global Glial Cell Line Derived Neurotrophic Factor share by Players 2023 (%)
  • Figure 12. BCG Matrix for key Companies
  • Figure 13. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 14. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 15. Treeway BV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 16. Treeway BV (Netherlands) Revenue: by Geography 2023
  • Figure 17. UniQure NV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 18. UniQure NV (Netherlands) Revenue: by Geography 2023
  • Figure 19. Global Glial Cell Line Derived Neurotrophic Factor: by Type USD Million (2025-2030)
  • Figure 20. Global Glial Cell Line Derived Neurotrophic Factor: by Application USD Million (2025-2030)
  • Figure 21. South America Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 22. Asia Pacific Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 23. Europe Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 24. MEA Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
  • Figure 25. North America Glial Cell Line Derived Neurotrophic Factor Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline Plc (United Kingdom)
  • Treeway BV (Netherlands)
  • UniQure NV (Netherlands)
Select User Access Type

Key Highlights of Report


Feb 2024 197 Pages 92 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Glial Cell Line Derived Neurotrophic Factor Market Quantitative research analysis
Global Glial Cell Line Derived Neurotrophic Factor Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline Plc (United Kingdom), Treeway BV (Netherlands) and UniQure NV (Netherlands) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancements in Technology have linked the Importance of GDNF in the Treatment of Parkinson’s disease," is seen as one of major influencing trends for Glial Cell Line Derived Neurotrophic Factor Market during projected period 2023-2030.
The Glial Cell Line Derived Neurotrophic Factor market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Glial Cell Line Derived Neurotrophic Factor Market Report?

Have a Query? Click Here

Other Related Reports

Expressed Competent Cells Comprehensive Study by Type (Chemically Competent Cells, Electro-Competent Cells), Application (Plasmid DNA, Bacterial Transformation, Cloning), Method (Natural Competence, ...
$ 3800
Plate Spreader Comprehensive Study by Type (Biochemical analysis, Biology lab equipment, Blood analysis system, Others), Application (Hospitals, Clinics, Laboratories), Usage Form (Cell holder, Bacte...
$ 3650
Partial Knee Replacement (PKR) Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Others), Implant (Fixed-Bearing Implants, Mobile-Bearing Implants, Media...
$ 3800
Biosimilars Treatment Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interfe...
$ 3750
Medicated Health Product Comprehensive Study by Type (Herbal Supplements, Hand Sanitizers, Body Powders, Pain Reliefs, Oral Health Products, Antiperspirant, Deodorant, Others), Sales Channel (Online,...
$ 3450
Hemoglobin A1c Monitoring Comprehensive Study by Type (Ion-exchange, High-performance liquid chromatography (HPLC), Immunoassay, Boronate affinity chromatography, Direct enzymatic assay), Application...
$ 3450